Patient‐reported quality‐of‐life outcomes after de‐escalated chemoradiation for human papillomavirus‐positive oropharyngeal carcinoma: Findings from a phase 2 trialJohn V. Hegde, Allen M. Chen, Megan E. Daly et al.|Cancer|2017Cited by 32
<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U. Kishan, Jérémie Calais, Kevin Flores et al.|Journal of Clinical Oncology|2025Cited by 24
Functional Outcomes After De-escalated Chemoradiation Therapy for Human Papillomavirus–Positive Oropharyngeal Cancer: Secondary Analysis of a Phase 2 TrialJohn V. Hegde, Allen M. Chen, Narek Shaverdian et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 14